Skip to main content

Advertisement

Table 4 Stratification analysis of IL-8 -251 T/A polymorphism in glioma

From: Association between interleukin 8–251 T/A and +781 C/T polymorphisms and glioma risk

  Cases TT TA AA
n (%) OR (95 %CI) P n (%) OR (95 %CI) P n (%) OR (95 %CI) P
Histology 300 96 (32.0) 1 (Reference)   120 (40.0) 1 (Reference)   84 (28.0) 1 (Reference)  
 Astrocytomas 223 73 (33.6) 1.02 (0.72,1.45) 0.90 88 (39.5) 0.99 (0.71,1.37) 0.94 62 (27.8) 0.99 (0.69,1.44) 0.97
 Ependymomas 43 12 (27.9) 0.87 (0.44,1.72) 0.69 18 (41.9) 1.05 (0.58,1.89) 0.88 13 (30.2) 1.08 (0.56,2.10) 0.82
 Oligodendrogliomas 19 6 (31.6) 0.99 (0.38,2.54) 0.98 8 (42.1) 1.05 (0.45,2.47) 0.91 5 (26.3) 0.94 (0.34,2.59) 0.91
 Mixed gliomas 15 5 (33.3) 1.04 (0.37,2.94) 0.94 6 (40.0) 1.00 (0.38,2.64) 1.00 4 (26.7) 0.95 (0.31,2.95) 0.93
WHO Grade 300 96 (32.0) 1 (Reference)   120 (40.0) 1(Reference)   84 (28.0) 1 (Reference)  
 I 17 6 (35.3) 1.10 (0.42,2.88) 0.84 7 (41.2) 1.03 (0.42,2.55) 0.95 4 (23.5) 0.84 (0.28,2.57) 0.76
 II 106 34 (32.1) 1.00 (0.64,1.57) 0.99 51 (48.1) 1.20 (0.81,1.79) 0.36 21 (19.8) 0.71 (0.42,1.20) 0.20
 III 76 28 (36.8) 1.15 (0.71,1.88) 0.57 33 (43.4) 1.09 (0.69,1.72) 0.73 15 (19.7) 0.71 (0.39,1.29) 0.26
 IV 101 28 (27.7) 0.87 (0.54,1.40) 0.56 29 (28.7) 0.72 (0.45,1.14) 0.16 44 (43.6) 1.56 (1.01,2.39) 0.04